SAN DIEGO--(BUSINESS WIRE)--Topera, Inc. today announced that its FDA-cleared RhythmView 3D mapping workstation will be discussed in 21 scientific presentations at the 34th Annual Scientific Sessions of the Heart Rhythm Society (HRS), May 8-11 in Denver, CO. The presentations will provide clinicians with additional information about the electrical sources that sustain atrial and ventricular arrhythmias and will share the scientific advances and best practices from the 14 US centers that have been using the RhythmView Workstation to assist in the diagnosis of arrhythmias.
“To see so many new authors reporting on their experiences using the RhythmView Workstation in their complex arrhythmia cases speaks to the intensifying interest in this 3D mapping platform as a means to improve clinical practice,” said Ruchir Sehra, MD, FHRS, Topera’s Chief Medical Officer. “This year, a majority of the scientific presentations involving RhythmView come from centers independent of the initial founding lab. We are pleased to see Topera’s technology taking a prominent role with an increasing number of electrophysiologists as they transform the care of their patients with heart rhythm disorders.”
Schedule of scientific presentations (All times are Mountain time, with events to be held at the Denver Four Seasons Hotel or Denver Convention Center):
Wednesday, May 8th
9:30 AM AF Summit - Four Seasons Hotel Ballroom 1
Atrial Fibrillation Sources Targeted for Focal Impulse and Rotor Modulation (FIRM) Are Stable in Location for Thousands of Cycles.
10:45 AM AF Summit - Four Seasons Hotel Ballroom 1
Catheter Ablation of Persistent and Long Standing Persistent AF.
6:00 PM Exhibit Hall - Denver Convention Center
PO01-110 – Conservation of Spatial Activation Patterns between Induced and Spontaneous Atrial Fibrillation in Individual Patients.
Thursday, May 9th
8:00 AM Four Seasons Hotel Ballroom 3
SP18: Special Session – Live Case Presentation: Ablation of atrial fibrillation by identification of rotor(s).
9:30 AM Exhibit Hall - Denver Convention Center
PO02-96 – Spectral Analysis of Atrial Action Potential Alternans: A Sensitive Clinical Index of Individual Propensity to Atrial Fibrillation.
11:30 AM Four Seasons Hotel Ballroom 3
LB01-05: Late-Breaking Clinical Trial: Treatment Of Paroxysmal Atrial Fibrillation By Targeted Elimination Of Stable Rotors And Focal Sources Without Pulmonary Vein Isolation: The Precise Rotor Elimination Without Concomitant Pulmonary Vein Isolation For Subsequent Elimination Of PAF (PRECISE) Trial.
2:00 PM Exhibit Hall - Denver Convention Center
PO03-73 - Focal Impulse and Rotor Modulation (FIRM) Ablation Remains Highly Successful In Patients with Unfavorable Demographics for Conventional Atrial Fibrillation Ablation: A substudy of the CONFIRM Trial.
PO03-113 - Triggers Consistently Lie Distant to the Atrial Fibrillation That They Initiate.
2:30 PM Bellco Theatre 1 - Denver Convention Center
AB12-05 - Atrial Fibrillation Sources Targeted for Focal Impulse and Rotor Modulation (FIRM) Are Stable in Location for Thousands of Cycles.
Friday, May 10th
9:05 AM Mile High Room 3B - Denver Convention Center
89: Featured Symposium - 30 years of Ablation: The Future.
9:30 AM Exhibit Hall - Denver Convention Center
MP03-01 - Results of Focal Impulse and Rotor Modulation (FIRM) for Atrial Fibrillation Are Equivalent Between Patients Treated in San Diego Compared with Sites New to FIRM Ablation: An Extended Multi-center Experience.
PO04-133 - Long-Term Success From FIRM Ablation Is Maintained Even if Acute Endpoint Is Not Achieved.
2:00 PM Exhibit Hall - Denver Convention Center
PO05-77 - Identification of Stable Atrial Fibrillation Rotors for FIRM Ablation Requires Good Electrode Contact For High Electrogram Fidelity.
PO05-142 - Global Surface ECG Phase Correlation Identifies Rotors in Early Human Ventricular Fibrillation.
PO05-185 - Focal Impulse and Rotor Modulation (FIRM) At a Stable Right Atrial Rotor Converts Persistent Atrial Fibrillation to Reentrant Atrial Tachycardia at the Same Location: Direct Evidence for Fibrillatory Conduction.
PO05-188 - Human Atrial Tachycardia at Cycle Length 156 ms Cannot Trigger Sustained Atrial Fibrillation After Focal Impulse and Rotor Modulation (FIRM).
2:30 PM Bellco Theatre 2 - Denver Convention Center
AB34-05 - Stable Atrial Fibrillation Rotors and Focal Sources Lie in Diverse Bi-Atrial Locations Often Remote from the Pulmonary Veins.
2:30 PM Room 108 - Denver Convention Center
AB41-05 - Rotors In Human Ventricular Fibrillation And Their Relationship To Ablation Sites For Ventricular Tachycardia.
2:45 PM Bellco Theatre 1 - Denver Convention Center
AB33-06 - Localized Focal Impulse and Rotor Modulation (FIRM) Terminates Atrial Fibrillation into Micro-Reentry, Residual Atrial Tachycardia or Sinus Rhythm: A Unifying Mechanistic Hypothesis.
4:35 PM Mile High Room 3C - Denver Convention Center
131 - How To Perform Substrate and Autonomic Ablation for AF: Mapping and Ablation of Substrate: Fragmented Signals and Rotors.
Saturday, May 11th
9:05 AM Mile High Room 1D - Denver Convention Center
158 - New Technologies for AF Ablation: Do They Add Value? - Rotor Mapping.
For a complete list of all presentations featuring the RhythmView Workstation to be presented at HRS, please visit www.toperamedical.com.
About Topera
Topera, Inc. (Topera Medical) a venture backed medical device company, has developed a novel 3D analysis and mapping system to assist electrophysiologists in the identification of the electrical source of complex cardiac arrhythmias. The Topera 3D Mapping System, which consists of the RhythmView Workstation and the FIRMap diagnostic catheter, is designed to improve patient outcomes by enabling electrophysiologists to view a dynamic representation of the electrical activity of the heart, supporting the diagnosis of and treatment planning for a variety of arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia. For additional information, visit www.toperamedical.com.
* The FIRMap Catheter is pending 510(k) clearance and is not available for sale.
* CE Marks for both the RhythmView Workstation and the FIRMap Catheter are currently pending.
